Insider Selling: Insmed Incorporated (NASDAQ:INSM) CFO Sells 3,470 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 3,470 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00. Following the completion of the sale, the chief financial officer now directly owns 114,736 shares in the company, valued at approximately $7,538,155.20. The trade was a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Sara Bonstein also recently made the following trade(s):

• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The stock was sold at an average price of $63.72, for a total value of $67,925.52.

Insmed Stock Down 0.7 %

Shares of INSM opened at $65.25 on Friday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $11.67 billion, a PE ratio of -11.76 and a beta of 1.12. The firm’s 50 day moving average is $71.23 and its 200-day moving average is $72.42. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. Insmed’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.10) EPS. Equities research analysts forecast that Insmed Incorporated will post -5.44 EPS for the current year.

Analyst Ratings Changes

INSM has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. raised their price target on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. Bank of America lifted their price objective on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Finally, Truist Financial reissued a “buy” rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Insmed has an average rating of “Moderate Buy” and a consensus price target of $83.67.

Institutional Investors Weigh In On Insmed

Several institutional investors and hedge funds have recently bought and sold shares of the company. V Square Quantitative Management LLC bought a new position in Insmed in the 3rd quarter valued at about $30,000. GAMMA Investing LLC boosted its position in shares of Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares during the last quarter. Blue Trust Inc. raised its position in Insmed by 2,348.8% during the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 1,879 shares in the last quarter. Finally, JCIC Asset Management Inc. bought a new stake in Insmed during the third quarter worth $133,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.